Significance of Combined Angiotensin Ⅱ Receptor Blocker and Carvedilol Therapy in Patients With Congestive Heart Failure and Arginine Variant

Atsushi	IWATA, MD
Shin-ichiro	MIURA, MD
Hiroaki	NISHIKAWA, MD
Akira	KAWAMURA, MD
Yoshino	MATSUO, BS
Hideto	SAKO, MD
Koichiro	KUMAGAI, MD, FJCC
Kunihiro	MATSUO, MD
Keijiro	SAKU, MD, FJCC

Abstract

Objectives. Angiotensin Ⅱ receptor blockers（ARBs）and β-blockers have contributed to longer life expectancies for patients with congestive heart failure. However, whether the use of ARBs is helpful for introducing carvedilol（β-blocker）is unclear when patients with symptomatic congestive heart failure are admitted to the hospital.

Methods. In this retrospective study, 27 patients with symptomatic congestive heart failure were given carvedilol upon admission. Five patients received carvedilol monotherapy（group A）, and 22 were treated with a combination of carvedilol and ARBs（group B）.

Results. There was no difference in medication between the groups except for ARBs. In addition, there were no significant differences in the decrease in plasma brain natriuretic peptide, or the improvement of left ventricular ejection fraction upon carvedilol treatment between the groups. Although there was no significant difference in the maintenance dose of carvedilol between the groups, the gross dose of carvedilol in group B was significantly lower than that in group A. In addition, the improvement of left ventricular ejection fraction in group B was positively correlated with the maintenance dose of carvedilol in patients who had wild-type β_1-adrenergic receptor at amino acid 389（arginine/arginine genotype）.

Conclusions. These results suggest that ARBs are helpful for introducing carvedilol in patients with the wild-type β_1-adrenergic receptor gene, and that treatment with combined treatment with ARB or analysis of the β_1-adrenergic receptor genotype may offer advantages to control congestive heart failure in the short term.

J Cardiol 2006 Jan ; 47（1）: 1―7

Key Words
■Angiotensin   ■Beta-adrenergic receptor blockers   ■Genetics
■Heart failure

福岡大学医学部 循環器内科：〒814―0180 福岡市城南区七隈7―45―1
Department of Cardiology, Fukuoka University Hospital, Fukuoka
Address for correspondence：MIURA S, MD, Department of Cardiology, Fukuoka University Hospital, Nanakuma 7―45―1, Jonan-ku, Fukuoka 814―0180
Manuscript received June 6, 2005 ; revised August 23 and October 6, 2005 ; accepted October 6, 2005
BS＝bachelor of science

INTRODUCTION

Congestive heart failure is associated with high mortality and morbidity. Many trials have demonstrated significant improvements with regard to survival and reduced hospitalization for patients who received angiotensin-converting enzyme inhibitors ACEIs and -blockers, and these results have guided the recommendations of national and international guidelines for the management of heart failure. In patients with congestive heart failure and reduced left ventricular ejection fraction LVEF , the results of clinical randomized trials have shown that ACEIs can provide life-saving and symptomatic benefits[1,3]. Furthermore, several double-blind, placebo-controlled, randomized studies performed in the United States and Europe have shown that -blockers have beneficial effects on mortality and mobility in patients with congestive heart failure[4,8]. In addition, -blocker carvedilol treatment for congestive heart failure patients is a highly cost-effective method of therapy in the Japanese medical environment[9].

However, as the prevalence of heart failure rises, its impact on morbidity, mortality, and healthcare costs exerts a heavy toll worldwide. A previous study[10] demonstrated that angiotensin receptor blockers ARBs prevented patients with heart failure from worsening. A recent result showed that treatment with combinations of -blockers and ACEIs reduced the mortality rate of patients with congestive heart failure[7]. Another study also demonstrated that the addition of ARBs to ACEIs and -blockers and other conventional treatments leads to a further clinically important reduction in relevant cardiovascular death and hospital admissions for heart failure in patients with congestive heart failure and improves LVEF[10,13]. In addition, carvedilol and losartan alone and in combination prevent ventricular remodeling after acute myocardial infarction in rats, with almost equivalent effect[14]. Several genetic polymorphisms have been identified in the $_1$-adrenergic receptor AR gene, and the genetic heterogeneity of $_1$-AR correlates with a pathophysiological role in patients with congestive heart failure. A recent investigation suggested that heart failure patients with the amino acid residue arginine Arg^{389} $_1$-AR variant showed improved left ventricular function when treated with carvedilol, a third-generation -blocker with vasodilatory and antioxidant actions, when compared with glycine Gly^{389} patients[15].

It would be worthwhile to determine whether treatment with ARBs is useful for introducing -blockers in patients with congestive heart failure. Therefore, we tested the hypothesis that the ARBs is useful for introducing carvedilol in patients with symptomatic congestive heart failure. We also examined the association between genetic variances of Arg^{389} in $_1$-AR and the results of carvedilol treatment in congestive heart failure.

SUBJECTS AND METHODS

Subjects

The subjects consisted of 27 patients with symptomatic congestive heart failure who were admitted to Fukuoka University Hospital. Patients had ischemic or non-ischemic cardiomyopathy with symptoms New York Heart Association NYHA functional class . Patients with the following conditions were excluded: valvular heart disease, hypertrophic obstructive cardiomyopathy, cardiogenic shock, systolic blood pressure 90 mmHg, bradycardia 60/min , grade or atrioventricular block, life-threatening arrhythmia, unstable angina, resting angina, cor-pulmonale, asthma, Raynaud phenomenon, and intermittent claudication. Hypertensive heart disease was defined by pressure of hypertension and left ventricular hypertrophy as assessed by echocardiography.

All patients were given carvedilol upon admission: 5 received carvedilol monotherapy group A , and 22 were treated with combined carvedilol and ARBs group B . In group B, 27% n 6 received 5 ± 1 mg/day of candesartan, 46% n 10 received 52 ± 13 mg/day of valsartan and 27% n 6 received 33 ± 5 mg/day of losartan. All patients in group B were introduced to carvedilol after ARB administration on admission to a hospital. ARB on admission and diuretics, digitalis, calcium channel blockers, vasodilators, and antiarrhythmic agents could be used concomitantly if necessary for treatment of congestive heart failure. We investigated blood pressure, heart rate, echocardiography, plasma brain natriuretic peptide BNP level, and the maintenance and total doses of carvedilol at two points on admission before treatment and when the patients left the hospital . The ethics committee of Fukuoka University Hospital approved this study.

Table 1 Baseline patient characteristics

	Group A n 5	Group B n 22
Age yr	56± 4	66± 2
Body mass index m²/kg	22± 2	23± 1
Male %	60	65
Alcohol use %	40	36
Current smoker %	80	41
Heart disease cause %		
Ischemic heart disease	0	44
Idiopathic cardiomyopathy	40	36
Hypertensive heart disease	40	16
Others	20	4
Concomitant disease %		
Hypertension	40	45
Diabetes mellitus	20	18
Hyperlipidemia	20	32
Medical treatment %		
Diuretics	80	82
Digitalis	20	23
NYHA class %		
/ /	20/80/0	0/74/26
LVEF %	24± 5	37± 3
LVDd mm	60± 6	57± 2
Systolic BP mmHg	110± 11	122± 4
Diastolic BP mmHg	75± 12	77± 4
Heart rate beats/min	91± 9	81± 4
BNP level pg/m*l*	789± 209	584± 112

Continuous values are mean± SE. p 0.05 vs group A.
Group A : Patients treated with carvediol. Group B : Patients treated with combined carvediol and angiotension receptor blockers.
NYHA New York Heart Association ; LVEF left ventricular ejection fraction ; LVDd left ventricular diastolic dimension ; BP blood pressure ; BNP brain natriuretic peptide.

Gene analysis

Genomic DNA was extracted from peripheral whole blood using the Genomix kit. For genotyping of the Arg389Gly polymorphism of the $_1$-AR gene, the polymerase chain reaction and restriction enzyme digestion were performed as described previously[16] .

Statistical analysis

Data are shown as the mean± standard error. Categorical variables were compared between groups by chi-square analysis. Differences in individual variables were analyzed by the unpaired *t*-test. Correlation between variables was examined


Fig. 1 Comparison of parameters in heart failure patients in groups A and B
No significant differences in the decrease in the BNP level   BNP,   values after carvedilol treatment minus those before treatment ; *A* or the increase in LVEF   LVEF ; *B* were observed between the groups.
Explanation of the groups and abbreviations as in Table 1.

by the Pearson correlation. A value of p 0.05 was regarded as significant. Data were analyzed using commercially available statistical software   Statview-J 5.0 ; Abacus Concepts Inc. .

RESULTS

Baseline patient characteristics are shown in **Table 1**. There were no significant differences in baseline characteristics between the two groups, except for the etiology of heart failure. None and 44% of the patients in groups A and B, respectively, had ischemic heart disease p 0.05 .

There were no significant differences in the decrease in the BNP level or the increase in LVEF   measured by M-mode echocardiography during carvedilol treatment between groups A and B **Fig. 1** . Since cardiac function in the groups recovered similarly, we did further statistical analysis. In addition, all patients in both groups became NYHA class   after treatment.

The gross and maintenance doses of carvedilol before and after treatment for introducing carvedilol are shown in **Fig. 2**. The gross dose indicates total amount of carvedilol during hospitalization for patients. Although there was no significant difference in the maintenance dose of carvedilol   group A : 7.5± 1.6 mg/day, group B : 9.3± 1.1 mg/day , the gross dose of carvedilol in group B 125± 12 mg was significantly lower than that in group A 204± 63 mg p 0.05 . Group B

Fig. 2 Gross and maintenance doses of carvedilol for introducing carvedilol in groups A and B

Although there was no significant difference in the maintenance dose of carvedilol *B* , the gross dose of carvedilol in group B was significantly lower than that in group A *A* ; *p* 0.05 . Total days of carvedilol administration is shown in *C* .
Gross dose of carvedilol   dose of carvedilol × total days of administration. Explanation of the groups as in Table 1.

tended to have a shorter total period of carvedilol administration compared to group A group A : 32 ± 7 days, group B : 23 ± 2 days, *p*   0.10 .

Fig. 3 compares the gross and maintenance doses of carvedilol before and after treatment for introducing carvedilol between the Arg/Arg *n* 14 and Arg/Gly *n*   8 groups in all patients. Five patients were excluded because of no approval to analyze DNA. There were no differences between the groups in baseline patient characteristics of age, body mass index, sex, drinking, smoking, heart disease cause, concomitant disease, medical treatment, NYHA class, LVEF, blood pressure, heart rate and BNP.

There were no significant differences in the gross or maintenance dose of carvedilol between the groups. Although there was no difference in the improvement of LVEF   LVEF   value after carvedilol treatment minus that before treatment between the Arg/Arg and Arg/Gly groups **Fig. 4 A** in all patients,   LVEF was positively correlated with the maintenance dose of carvedilol in group B patients who had the Arg/Arg genotype **Fig. 4 B** . In the Arg/Gly group, there was no correlation between LVEF and the maintenance dose of carvedilol *p*   0.10 . If a patient with congestive heart failure and the wild-type   1-AR gene position 389 is Arg/Arg receives combination therapy with ARBs for the introduction of carvedilol, a higher maintenance dose of carvedilol may more

effectively improve cardiac function.

DISCUSSION

Our results support the hypothesis that ARBs and   -blockers have beneficial effects for patients with heart failure. Previous studies have demonstrated that ARBs have long-term benefits and reduce cardiovascular death and hospital admissions for heart failure. Our results suggest that ARBs also have a short-term benefit, *i.e.*, additional treatment with ARBs can reduce the gross dose of carvedilol. Therefore, the use of carvedilol combined with ARBs may be useful for introducing carvedilol in patients with heart failure.

Once the onset of heart failure has occurred, a vicious cycle is initiated. After a sizable myocardial loss to precipitate heart failure, neurohormonal activation, especially of the sympathetic nerve system and the renin-angiotensin system, results in further losses of cardiac myocytes through apoptosis and necrosis. A primary objective of treatment is to prevent the further loss of cardiac myocytes[17] , by reducing the recurrence of myocardial infarctions, myocarditis, or cardiomyopathic processes. The former can be effectively achieved by inhibiting the renin-angiotensin system or the sympathetic system. The latter can also be partly achieved by treatment with angiotensin converting enzyme inhibitors and possibly ARBs[18,19] . Administration of   -blocker normalized the abundance of

Fig. 3 Representative genetic variances in three individuals, gross and maintenance doses of carvediol

A: Representative genetic variances of β_1-AR at amino acid 389 in three individuals. Polymerase chain reaction fragments were digested with the restriction endonuclease Bcg I, which did not digest the Arg-389 product because of the guanine to cytosine transition.

B,C: Gross *B* and maintenance *C* doses of carvedilol in the Arg/Arg n 14 and Arg/Gly groups n 8 are shown. None of the subjects in this study were Gly/Gly. There were no significant differences in the gross and maintenance doses of carvedilol between the groups.

Arg arginine; Gly glycine; bp base paire.

Fig. 4 LVEF in the Arg/Arg and Arg/Gly groups *A*, and LVEF was positively correlated with the maintenance dose of carvedilol in group B patients who had the Arg/Arg genotype y 3.222 0.801x, r 0.674, p 0.05; *B*.

Explanation of group B and abbreviation as in Table 1, Fig. 3.

myocyte Ca^2 regulatory proteins and improved Ca^2 handling[20]. In addition, β-blockers can effectively suppress the sympathetic system, thus interrupting the downward spiral caused by the vicious cycle in patients with heart failure, and prevent further losses of cardiac myocytes. Accordingly, the accelerated deterioration of cardiac pumping capability can be ameliorated by therapy aimed at inhibiting angiotensin and/or β-adrenergic effects using ARBs and/or β-blockers. The combination therapy with carvedilol and ARBs may be more potent than individual treatments through the combined beneficial mechanisms for controlling heart failure as seen in this study.

Over the past decade, increasing evidence has accumulated to indicate that angiotensin is involved in the development of atherosclerosis, myocardial infarction, vascular and myocardial remodeling, and heart failure[21,22]. In the case of heart failure, angiotensin type 1 AT_1 receptors expressed in myocardial cells are activated, which causes consequent cellular hypertrophy, proliferation, and apoptosis. ARBs strongly block AT_1 receptors, and reduce cardiovascular death and hospital admissions for heart failure. Up-regulation of angiotensin caused by ARBs stimulates AT_2 receptor. Other mechanisms of action, such as AT_2 receptor effects, and the anti-oxidant[23] or anti-fibrotic effects of ARBs[24], may also contribute to the improvement of heart failure.

According to a previous epidemiological study, the β_1-AR Ser49Gly variant might be associated with a decreased risk of morbidity and mortality in patients with congestive heart failure[25]. Also, a lack of polymorphic α_{2c}-AR α_{2c} Del322 325 and abnormality of β_1-AR Arg389Gly act synergistically to increase the risk of heart failure in blacks[26]. A recent study demonstrated that the human Arg[389] variant predisposes patients to heart failure by instigating hyperactive signaling programs which lead to depressed receptor coupling and ventricular dysfunction, and influences the therapeutic response to β_1-AR blockade. Heart failure patients with Arg[389] homozygosis showed improved left ventricular function during long-term carvedilol treatment compared to Gly[389] patients.

Although we did not note any differences in the improvement of left ventricular function for introducing carvedilol between the Arg/Arg and Arg/Gly groups, this may have been due to the short duration of this study. This study found that the Arg^{389} variant in β$_1$-AR may be useful for introducing carvedilol in heart failure patients because a higher maintenance dose of carvedilol was more effective for improving cardiac function in patients with the wild-type β$_1$-AR gene Arg/Arg at position 389 . If heart failure patients who have the Arg/Arg genotype and receive combination therapy with ARBs for introducing carvedilol, a higher maintenance dose of carvedilol might be recommended.

Study limitations

This study has several important limitations.

First, there was a difference in the etiology of heart failure between groups A and B. However, this difference did not affect our main conclusion that ARBs are helpful for introducing carvedilol in patients with the wild-type β$_1$-AR gene. Second, the sample size is small, which limited our ability to determine significance. Our study was a nonrandomized, retrospective, observational study. A large randomized controlled trial of statins in patients with coronary artery disease is warranted to evaluate the potential benefits of these agents.

CONCLUSIONS

Additional treatment with ARBs and the analysis of Arg^{389} variant in β$_1$-AR in patients with congestive heart failure may be helpful for introducing carvedilol, and treatment with the combination of carvedilol and ARBs may have advantages over

389

1

: ARB

ARB

: 27

2   5   22   ARB

: ARB   Na

ARB

ARB   1

389   Arg/Arg

: ARB   1   389   Arg/Arg

ARB   1

References

1 The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study CONSENSUS . N Engl J Med 1987; **316**: 1429 1435

2 The SOLVD Investigators: Effect of enalapril on survival

in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; **325**: 293 302

3 Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; **273**: 1450 1456

4 Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failures Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; **334**: 1349 1355

5 Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997; **349**: 375 380

6 Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival Study Groups: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; **344**: 1651 1658

7 CIBIS- Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study CIBIS- : A randomized trial. Lancet 1999; **353**: 9 13

8 MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure MERIT-HF . Lancet 1999; **353**: 2001 2007

9 Inomata T, Izumi T, Kobayashi M: Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. Circ J 2004; **68**: 35 40

10 Matsumori A, on behalf of the Assessment of Response to Candesartan in Heart Failure in Japan ARCH-J Study Investigators: Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003; **5**: 669 677

11 McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, for the CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003; **362**: 767 771

12 McKelvie RS, Rouleau JL, White M, Afzal R, Young JB, Maggioni AP, Held P, Yusuf S: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur Heart J 2003; **24**: 1727 1734

13 Hara Y, Hamada M, Shigematsu Y, Ohtsuka T, Ogimoto A, Suzuki J, Higaki J: Effect of beta-blocker therapy in elderly patients with dilated cardiomyopathy. Circ J 2003; **67**: 826 829

14 Yang YJ, Tang YD, Ruan YM, Zhang P, Zhou YW, Wang Gao RL, Chen JL, Chen ZJ: Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. Circ J 2003; **67**: 159 162

15 Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB: $_1$-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; **9**: 1300 1305

16 Maqbool A, Hall AS, Ball SG, Balmforth AJ: Common polymorphisms of beta1-adrenoceptor: Identification and rapid screening assay. Lancet 1999; **353**: 897

17 Goldspink DF, Burniston JG, Tan LB: Cardiomyocyte death and the ageing and failing heart. Exp Physiol 2003; **88**: 447 458

18 Tan LB, Benjamin IJ, Clark WA: Beta-adrenergic receptor desensitisation may serve a cardioprotective role. Cardiovasc Res 1992; **26**: 608 614

19 Goussev A, Sharov VG, Shimoyama H, Tanimura M, Lesch M, Goldstein S, Sabbah HN: Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol 1998; **275**: H626 H631

20 Kubo H, Margulies KB, Piacentino , Gaughan JP, Houser SR: Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 2001; **104**: 1012 1018

21 Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999; **340**: 115 126

22 Vaughan DE: AT_1 receptor blockade and atherosclerosis: Hopeful insights into vascular protection. Circulation 2000; **101**: 1496 1497

23 Nickenig G, Harrison DG: The AT 1 -type angiotensin receptor in oxidative stress and atherogenesis: Part : Oxidative stress and atherogenesis. Circulation 2002; **105**: 393 396

24 Opie LH, Sack MN: Enhanced angiotensin activity in heart failure: Reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res 2001; **88**: 654 658

25 Borjesson M, Magnusson Y, Hjalmarson A, Andersson B: A novel polymorphism in the gene coding for the beta 1 -adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; **21**: 1853 1858

26 Small KM, Wagoner LE, Levine AM, Kardia SL, Liggett SB: Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; **347**: 1135 1142